Premature babies face many health hurdles. One common treatment involves giving them early injections called erythropoiesis-stimulating agents, or ESAs. These drugs help the body make more red blood cells. A new review looked at 37 studies involving 6,724 infants to see if starting these drugs before eight days of life helps or harms them. The findings offer hope for families worried about long-term brain health.
The data suggests these early injections probably do not change the risk of death during the initial hospital stay. However, there is a potential benefit for brain development. The review found that moderate to severe neurodevelopmental impairment at 18 to 26 months may be reduced. This is a significant finding for parents hoping their child will reach developmental milestones without delays.
Beyond brain health, the drugs also seem to help with other serious conditions. They probably reduce the risk of necrotizing enterocolitis, a dangerous gut infection. They also likely lower the risk of severe bleeding in the brain. The review found no difference in the risk of retinopathy of prematurity, a condition affecting the retina. Infants receiving these drugs also needed fewer red blood cell transfusions.
It is important to remember that the certainty of the evidence varied. Some results were based on fewer studies or showed higher risk of bias. The review did not report specific safety signals like side effects or discontinuations. Future research should focus on cost and feasibility. Until then, doctors must weigh these potential benefits against the current uncertainty for each individual baby.